Enanta Pharmaceuticals (ENTA) Receivables (2012 - 2026)

Enanta Pharmaceuticals (ENTA) has 15 years of Receivables data on file, last reported at $7.8 million in Q1 2026.

• For the quarter ending Q1 2026, Receivables rose 14.97% year-over-year to $7.8 million; the trailing twelve-month figure through Mar 2026 stood at $7.8 million (up 14.97% YoY), and the FY2025 full-year result was $6.9 million, up 3.55% from the prior year.
• Receivables for Q1 2026 stood at $7.8 million, down from $8.5 million in the prior quarter.
• Across five years, Receivables topped out at $22.6 million in Q4 2022 and bottomed at $6.6 million in Q3 2024.
• The 5-year median for Receivables is $8.3 million (2025), against an average of $12.0 million.
• The widest annual swing landed in 2023, when Receivables plunged 63.81%; it then gained 14.97% in 2026.
• A 5-year view of Receivables shows it stood at $22.6 million in 2022, then slumped by 63.81% to $8.2 million in 2023, then declined by 5.57% to $7.7 million in 2024, then gained by 10.04% to $8.5 million in 2025, then decreased by 8.05% to $7.8 million in 2026.
• The last three Receivables figures came in at $7.8 million (Q1 2026), $8.5 million (Q4 2025), and $6.9 million (Q3 2025), per Business Quant data.

Peer Comparison